Kintara Therapeutics (NASDAQ:KTRA) Inc (NASDAQ:KTRA) CEO Saiid Zarrabian tells Proactive its VAL-083 treatment arm in the Global Coalition for Adaptive Research (GCAR) registrational Phase 2/3 clinical trial for glioblastoma multiforme (GBM) has now been activated in 26 US sites.
Zarrabian explains why speed of site enrollment is so important, and how the group managed to establish enrollment at sites within a span of a seven months. He says typically, it will take around 2 years to enroll at these kind of sites.